Dr. David R. Fermin, M.D.
Heart Failure & Transplant Cardiology (Advanced Heart Failure and Transplant Cardiology Physician)
- Medicare participating
At a glance
- Medical school
- University of Minnesota Medical School (2006)
- Years since graduation
- 20
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 286
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Medical school: University of Minnesota Medical School
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Advanced Heart Failure and Transplant Cardiology Physician primary
MI license 4301104120 -
Cardiovascular Disease Physician
MI license 4301104120 · MN license 50639
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Heart Failure & Transplant Cardiology per capita by county →
Where they work
Hospitals
- Spectrum Health Grand Rapids, MI
- Spectrum Health United Hospital Greenville, MI
- Corewell Health Big Rapids Hospital Big Rapids, MI
- Corewell Health Zeeland Hospital Zeeland, MI
- Corewell Health Pennock Hospital Hastings, MI
Medical groups
- Spectrum Health Primary Care PArtners (2,294 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 286
- Services billed
- 646
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 128 | 128 |
| Physician review, interpretation, and patient management of home inr testing for patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets medicare coverage criteria; testing not occurring more frequent | 123 | 99 |
| Critical care, first 30-74 minutes | 47 | 18 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 45 | 27 |
| Established patient office or other outpatient visit, 30-39 minutes | 41 | 37 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 36 | 36 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 32 | 29 |
| Ultrasound of heart, follow-up | 26 | 25 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 25 | 25 |
| Evaluation of lower heart chamber assist device | 24 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Spironolactone Other prescribers in Grand Rapids, MI | 385 |
| Vyndamax (tafamidis) | 256 |
| Metoprolol Succinate Other prescribers in Grand Rapids, MI | 244 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Grand Rapids, MI | 185 |
| Eliquis (apixaban) Other prescribers in Grand Rapids, MI | 184 |
| Entresto (sacubitril/valsartan) Other prescribers in Grand Rapids, MI | 179 |
| Furosemide Other prescribers in Grand Rapids, MI | 122 |
| Torsemide Other prescribers in Grand Rapids, MI | 113 |
| Carvedilol Other prescribers in Grand Rapids, MI | 105 |
| Jardiance (empagliflozin) Other prescribers in Grand Rapids, MI | 103 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 46 payments worth $38,974 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $37,960 |
|---|---|
| Pfizer Inc. | $713 |
| Abbott Laboratories | $191 |
| Alnylam Pharmaceuticals Inc. | $96.81 |
| Zoll Services LLC (a/k/a Zoll Lifecor Corp) | $12.99 |
| Compensation for services other than consulting (speaking, faculty) | $36,510 |
|---|---|
| Food and Beverage | $998 |
| Consulting Fee | $880 |
| Travel and Lodging | $527 |
| Education | $59.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Jul 16, 2025 | Compensation for services other than consulting (speaking, faculty) | $6,960 |
| E.r. Squibb & Sons, L.l.c. Feb 21, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,800 |
| E.r. Squibb & Sons, L.l.c. Dec 15, 2025 | Compensation for services other than consulting (speaking, faculty) CAMZYOS · Cardiovascular | $5,800 |
| E.r. Squibb & Sons, L.l.c. Apr 7, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,640 |
| E.r. Squibb & Sons, L.l.c. Nov 5, 2025 | Compensation for services other than consulting (speaking, faculty) CAMZYOS · Cardiovascular | $4,640 |
| E.r. Squibb & Sons, L.l.c. Dec 8, 2025 | Compensation for services other than consulting (speaking, faculty) CAMZYOS · Cardiovascular | $4,640 |
| E.r. Squibb & Sons, L.l.c. Jul 11, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,480 |
| E.r. Squibb & Sons, L.l.c. Oct 7, 2025 | Consulting Fee | $580 |
| Pfizer Inc. Jan 21, 2025 | Compensation for services other than consulting (speaking, faculty) VYNDAMAX · CARDIOVASCULAR | $550 |
| E.r. Squibb & Sons, L.l.c. Jan 6, 2025 | Consulting Fee | $300 |
All 15 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Dec 15, 2025 | Compensation for services other than consulting (speaking, faculty) CAMZYOS · Cardiovascular | $5,800 |
| E.r. Squibb & Sons, L.l.c. Dec 8, 2025 | Compensation for services other than consulting (speaking, faculty) CAMZYOS · Cardiovascular | $4,640 |
| E.r. Squibb & Sons, L.l.c. Nov 5, 2025 | Compensation for services other than consulting (speaking, faculty) CAMZYOS · Cardiovascular | $4,640 |
| E.r. Squibb & Sons, L.l.c. Oct 7, 2025 | Consulting Fee | $580 |
| E.r. Squibb & Sons, L.l.c. Jul 18, 2025 | Travel and Lodging travel to Dearborn, MI | $107 |
| E.r. Squibb & Sons, L.l.c. Jul 16, 2025 | Compensation for services other than consulting (speaking, faculty) | $6,960 |
| E.r. Squibb & Sons, L.l.c. Jul 11, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,480 |
| E.r. Squibb & Sons, L.l.c. Jul 7, 2025 | Travel and Lodging travel to Dearborn, MI | $107 |
| Alnylam Pharmaceuticals Inc. Jun 12, 2025 | Education AMVUTTRA · Genetic Disease · in-kind | $59.00 |
| E.r. Squibb & Sons, L.l.c. May 28, 2025 | Travel and Lodging travel to Dearborn, MI | $233 |
| E.r. Squibb & Sons, L.l.c. Apr 7, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,640 |
| E.r. Squibb & Sons, L.l.c. Feb 21, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,800 |
| E.r. Squibb & Sons, L.l.c. Feb 14, 2025 | Travel and Lodging travel to Kalamazoo, MI | $79.10 |
| Pfizer Inc. Jan 21, 2025 | Compensation for services other than consulting (speaking, faculty) VYNDAMAX · CARDIOVASCULAR | $550 |
| E.r. Squibb & Sons, L.l.c. Jan 6, 2025 | Consulting Fee | $300 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 2 companies. The companies reported $228,243 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
E.r. Squibb & Sons, L.l.c. - SONATA-HCM / Sotagliflozin / LX4211
Lexicon Pharmaceuticals, Inc. - A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic C…
E.r. Squibb & Sons, L.l.c. - SONATA-HCM
Lexicon Pharmaceuticals, Inc. - Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461
E.r. Squibb & Sons, L.l.c. · Completed · NCT02329184
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.